D. E. Shaw & Co. Inc. Buys 62,889 Shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT)

D. E. Shaw & Co. Inc. boosted its stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT) by 27.9% during the fourth quarter, Holdings Channel reports. The firm owned 288,409 shares of the company’s stock after purchasing an additional 62,889 shares during the quarter. D. E. Shaw & Co. Inc.’s holdings in ClearPoint Neuro were worth $4,436,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also added to or reduced their stakes in the stock. R Squared Ltd bought a new position in shares of ClearPoint Neuro during the 4th quarter valued at $32,000. Barclays PLC grew its holdings in shares of ClearPoint Neuro by 24.3% in the third quarter. Barclays PLC now owns 5,674 shares of the company’s stock worth $64,000 after acquiring an additional 1,109 shares during the period. AlphaQuest LLC purchased a new stake in ClearPoint Neuro during the fourth quarter valued at $80,000. Tower Research Capital LLC TRC bought a new position in ClearPoint Neuro in the fourth quarter valued at about $93,000. Finally, JPMorgan Chase & Co. lifted its holdings in ClearPoint Neuro by 58.7% in the third quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company’s stock valued at $110,000 after acquiring an additional 3,612 shares during the period. Institutional investors own 30.08% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Lake Street Capital boosted their price target on ClearPoint Neuro from $17.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, January 21st. B. Riley upped their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Finally, Stifel Nicolaus upped their price target on shares of ClearPoint Neuro from $19.00 to $25.00 and gave the company a “buy” rating in a research report on Tuesday, April 1st.

ClearPoint Neuro Stock Up 2.0%

NASDAQ CLPT opened at $13.18 on Friday. ClearPoint Neuro, Inc. has a 52 week low of $5.11 and a 52 week high of $19.22. The firm has a market capitalization of $368.90 million, a P/E ratio of -19.10 and a beta of 1.03. The company has a 50-day moving average price of $12.87 and a 200-day moving average price of $14.23.

ClearPoint Neuro (NASDAQ:CLPT) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.15) by ($0.07). ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. The business had revenue of $8.49 million for the quarter, compared to analysts’ expectations of $8.21 million. As a group, equities research analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 EPS for the current year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.